남성 유방암 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the male breast cancer market size is expected to grow from USD 4.49 billion in 2025 to USD 4.65 billion in 2026 and is forecast to reach USD 5.63 billion by 2031 at 3.92% CAGR over 2026-2031.

This report is Segmented by Cancer Type (Infiltrating Ductal, DCIS, Paget Disease, Inflammatory, Invasive Lobular, Diagnosis, Imaging, and More), by Treatment Modality (Local Therapy, Systemic Therapy, Supportive Care), End User (Hospitals, Specialty Clinics, Academic Centers, Ascs) and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Male Breast Cancer Market Trends and Insights

Rising Diagnosis And Awareness

Male breast cancer has long been identified later than female breast cancer, and published evidence placed average diagnostic delay in men at 14 to 21 months compared with 1 to 4 months in women. That delay has direct commercial implications for the male breast cancer market because late recognition pushes patients into more resource-intensive treatment pathways after symptoms have already advanced. Clinical reports also showed that male presentation is still often triggered by self-detection rather than structured examination, which keeps imaging and biopsy demand closely tied to awareness efforts among the public and frontline physicians. As more general practitioners recognize the disease earlier, referral volumes move faster into imaging, pathology, and endocrine therapy, and that broadens demand across the male breast cancer market rather than in one care setting alone. Earlier diagnosis also changes the treatment mix over time, because patients identified before wide metastatic spread are more likely to receive longer courses of guided systemic care and monitored follow-up.

Expansion Of CDK4/6, PARP, And HER2-Targeted Options

The treatment range in the male breast cancer market has widened since real-world evidence first helped extend CDK4/6 inhibitor use to men with HR-positive, HER2-negative metastatic disease. Ribociclib then moved further into early disease after the September 2024 FDA approval for adjuvant use in high-risk early breast cancer, and that label explicitly included men in the NATALEE trial population. Real-world clinical data from Turkey also supported class performance in men, with overall response rates of 84.0% for palbociclib and 76.2% for ribociclib in first-line treatment of metastatic HR-positive, HER2-negative disease. PARP inhibitors add another growth layer because a German registry found that 12.6% of men with early breast cancer met adjuvant olaparib eligibility criteria under the OlympiA framework, which is meaningful in a rare-disease setting. New approvals, such as inavolisib in October 2024 and datopotamab deruxtecan in January 2025, show that the male breast cancer market is gradually gaining access to the same targeted treatment architecture that already shapes female breast cancer care.

Tiny Patient Pool Constrains Trials And ROI

The rare nature of the disease remains a structural drag on the male breast cancer market because the United States is expected to record only 2,670 new male cases in 2026, compared with 316,950 female cases. That gap makes male-only interventional trials difficult to recruit, and weak recruitment then limits the amount of sex-specific evidence available for regulators, payers, and guideline writers. A German registry analysis showed how wide that gap remains, since men represented only 0.3% to 0.6% of participants in major adjuvant trials even though 12.6% to 47.6% of men in the registry would have met trial eligibility criteria. This keeps the male breast cancer market dependent on extrapolated female data and real-world evidence rather than direct male Phase III programs, which can slow reimbursement decisions for newer drugs. The same limitation is especially relevant for PARP inhibitors, next-generation endocrine agents, and newer combination approaches, where male-specific outcome evidence is still limited as of 2026.

Other drivers and restraints analyzed in the detailed report include:

1. Wider Germline BRCA And Tumor Biomarker Testing
2. Better Oncology Access In Emerging Markets
3. Stigma And Low Clinical Suspicion Delay Diagnosis

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Infiltrating ductal carcinoma accounted for 76.23% share in 2025, which made it the central revenue base for the male breast cancer market by cancer type. That concentration is consistent with broader clinical literature showing that infiltrating ductal tumors make up most male breast cancer cases and are usually estrogen receptor positive. Because this subtype is usually hormone-driven, the care pattern in the male breast cancer market stays closely tied to endocrine therapy, CDK4/6 inhibitors, and long follow-up periods rather than to chemotherapy alone. The dominance of ductal disease also makes pathology and receptor testing more important, because treatment selection depends on defining ER, PR, and HER2 status clearly at diagnosis. Rare subtypes such as inflammatory breast cancer and Paget disease represent small revenue pools, but they still create high-intensity treatment episodes because they often present with more aggressive clinical behavior.

Ductal carcinoma in situ is forecast to expand at 4.48% CAGR through 2031, making it the fastest-growing cancer type within the male breast cancer market. The key reason is that wider germline testing and surveillance in BRCA carriers are increasing the chance of detection before invasive transformation. This earlier-stage mix supports more imaging, biopsy, and planned surgery, and it gradually shifts part of the male breast cancer industry toward controlled early intervention rather than late-stage rescue treatment. Invasive lobular carcinoma remains uncommon in men because lobular tissue is sparse in normal male breast anatomy, so its commercial weight stays limited in the male breast cancer market. Even so, these less common forms still matter clinically because they broaden the need for specialized pathology review and hormone-focused management in selected patients.

Imaging captured 38.28% of the diagnosis segment in 2025, which gave it the largest position within diagnostic spending in the male breast cancer market. In practice, mammography and ultrasound remain the main first-line tools, and U.S. surgical oncology guidance supports ultrasound first for men under 25 with indeterminate palpable masses and mammography for men aged 25 or older. That structure keeps imaging volume steady because most patients still present after noticing a lump or local change rather than through organized screening. PET and MRI occupy smaller positions, but they remain important for staging and treatment response assessment in advanced disease, especially when clinicians need a broader disease map. As awareness improves, imaging demand in the male breast cancer industry will continue to be supported by earlier referral rather than only by metastatic workup.

Pathology is the fastest-growing diagnostic category at 5.22% CAGR through 2031, reflecting the move toward biomarker-led decisions across the male breast cancer market. Receptor profiling for ER, PR, and HER2 is now fundamental to therapy choice, and germline BRCA testing has also shifted from selective use to a standard recommendation for newly diagnosed men. Companion diagnostics are also deepening revenue per patient episode, as shown by the approval of FoundationOne Liquid CDx alongside inavolisib for PIK3CA mutation detection. The January 2026 CMS decision on TruSight Oncology Comprehensive gave the male breast cancer market another push by making broader genomic profiling more accessible to Medicare beneficiaries. Over time, this means more of the value in diagnosis will come from interpretation and molecular stratification rather than from imaging alone.

Geography Analysis

North America accounted for 42.39% share of the male breast cancer market size in 2025, which kept it in the lead among all regions. The region's strength comes from established oncology infrastructure, broad reimbursement for advanced therapies, and a stronger real-world evidence ecosystem that supports male use even when randomized male-only data remain limited. The 2024 ASCO and Society of Surgical Oncology update on universal germline testing for men with breast cancer also supports more consistent biomarker identification and downstream treatment use in the U.S. segment of the male breast cancer market. Real-world evidence from the POLARIS study further strengthened this base, with male patients treated with palbociclib showing a median real-world progression-free survival of 19.8 months. Canada adds to the region's depth through aligned germline testing recommendations and regulatory support for ribociclib in male patients, which keeps North America the most developed regional cluster in the male breast cancer market.

Europe remained the second-largest regional grouping in the male breast cancer market, led by Germany, France, the United Kingdom, and Italy. The region gained an important boost when ribociclib was approved in Europe for adjuvant early breast cancer after a trial program that explicitly included men, which improved the credibility of male access in earlier-stage disease. Germany's registry data also showed that 47.6% of men with early breast cancer met ribociclib eligibility criteria under NATALEE, which points to sizable untreated or undertreated opportunity within the regional male breast cancer market. Even with this progress, Europe still faces a translation gap between trial eligibility and routine uptake, which means growth depends as much on implementation discipline as on new approvals.

Asia-Pacific is projected to grow at 5.87% CAGR through 2031, making it the fastest-expanding regional block in the male breast cancer market. China is the main driver because it recorded 16,956 new male cases in 2021 and has seen incidence rise much faster than the global average over the last 3 decades. East Asia also has a reported HER2 positivity rate of 17% in male breast cancer, which is materially higher than the 8% level reported for Europe and the United States, and that creates stronger regional demand for HER2-directed therapy. Japan supports uptake through national insurance coverage for BRCA1 and BRCA2 germline testing and through clinical guidance that includes male disease in practice frameworks. Middle East and Africa as well as South America are smaller today, but they remain part of the longer runway for the male breast cancer market as GCC infrastructure investment, awareness programs, and insurance expansion gradually improve diagnosis and treatment access despite persistent late-stage presentation in several lower-resource settings.

1. AstraZeneca
2. Bristol-Myers Squibb
3. Daiichi Sankyo
4. Eisai
5. Eli Lilly and Company
6. Exact Sciences
7. F. Hoffmann-La Roche Ltd / Genentech, Inc.
8. GE HealthCare Technologies Inc.
9. Gilead Sciences
10. Hologic
11. Illumina
12. Merck
13. Novartis
14. Pfizer
15. Sanofi
16. Siemens Healthineers
17. Sun Pharmaceuticals Industries
18. Teva Pharmaceutical Industries
19. Thermo Fisher Scientific
20. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diagnosis and Awareness
  • 4.2.2 Expansion of CDK4/6, PARP, And HER2-Targeted Options
  • 4.2.3 Wider Germline BRCA and Tumor Biomarker Testing
  • 4.2.4 Better Oncology Access in Emerging Markets
  • 4.2.5 Male-Inclusion Pressure in Breast Cancer Trials
  • 4.2.6 Real-World-Evidence Label Expansion for Men
• 4.3 Market Restraints
  • 4.3.1 Tiny Patient Pool Constrains Trials and ROI
  • 4.3.2 Stigma And Low Clinical Suspicion Delay Diagnosis
  • 4.3.3 Tamoxifen Side Effects and Poor Adherence
  • 4.3.4 Women-Centric Reimbursement and Evidence Pathways
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Cancer Type
  • 5.1.1 Infiltrating Ductal Carcinoma
  • 5.1.2 Ductal Carcinoma In Situ
  • 5.1.3 Paget Disease of the Nipple
  • 5.1.4 Inflammatory Breast Cancer
  • 5.1.5 Invasive Lobular Carcinoma
• 5.2 By Diagnosis
  • 5.2.1 Imaging
    • 5.2.1.1 Mammography
    • 5.2.1.2 Ultrasound
    • 5.2.1.3 Magnetic Resonance Imaging
    • 5.2.1.4 Computed Tomography
    • 5.2.1.5 Positron Emission Tomography
  • 5.2.2 Pathology
    • 5.2.2.1 Core Needle Biopsy
    • 5.2.2.2 Fine Needle Aspiration Biopsy
    • 5.2.2.3 Excisional Biopsy
  • 5.2.3 Biomarker and Genetic Testing
    • 5.2.3.1 Estrogen Receptor / Progesterone Receptor Testing
    • 5.2.3.2 HER2 Testing
    • 5.2.3.3 Germline BRCA and Hereditary Cancer Panel Testing
    • 5.2.3.4 Tumor Genomic Profiling
• 5.3 By Treatment Modality
  • 5.3.1 Local Therapy
    • 5.3.1.1 Surgery
      • 5.3.1.1.1 Mastectomy
      • 5.3.1.1.2 Breast-Conserving Surgery
      • 5.3.1.1.3 Sentinel Lymph Node Biopsy
      • 5.3.1.1.4 Axillary Lymph Node Dissection
    • 5.3.1.2 Radiation Therapy
  • 5.3.2 Systemic Therapy
    • 5.3.2.1 Endocrine Therapy
      • 5.3.2.1.1 Tamoxifen
      • 5.3.2.1.2 Aromatase Inhibitor Plus GnRH Analogue
      • 5.3.2.1.3 Fulvestrant
    • 5.3.2.2 Chemotherapy
      • 5.3.2.2.1 Neoadjuvant Chemotherapy
      • 5.3.2.2.2 Adjuvant Chemotherapy
      • 5.3.2.2.3 Metastatic-Line Chemotherapy
    • 5.3.2.3 Targeted Therapy
      • 5.3.2.3.1 CDK4/6 Inhibitors
      • 5.3.2.3.2 HER2-Targeted Therapy
      • 5.3.2.3.3 PARP Inhibitors
      • 5.3.2.3.4 PI3K / AKT / mTOR-Pathway Therapies
    • 5.3.2.4 Immunotherapy
  • 5.3.3 Supportive Care
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Cancer Specialty Clinics
  • 5.4.3 Academic and Research Centers
  • 5.4.4 Ambulatory Surgical Centers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 AstraZeneca PLC
  • 6.3.2 Bristol Myers Squibb Company
  • 6.3.3 Daiichi Sankyo Company, Limited
  • 6.3.4 Eisai Co., Ltd.
  • 6.3.5 Eli Lilly and Company
  • 6.3.6 Exact Sciences Corporation
  • 6.3.7 F. Hoffmann-La Roche Ltd / Genentech, Inc.
  • 6.3.8 GE HealthCare Technologies Inc.
  • 6.3.9 Gilead Sciences, Inc.
  • 6.3.10 Hologic, Inc.
  • 6.3.11 Illumina, Inc.
  • 6.3.12 Merck & Co., Inc.
  • 6.3.13 Novartis AG
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Sanofi S.A.
  • 6.3.16 Siemens Healthineers AG
  • 6.3.17 Sun Pharmaceutical Industries Ltd.
  • 6.3.18 Teva Pharmaceutical Industries Ltd.
  • 6.3.19 Thermo Fisher Scientific Inc.
  • 6.3.20 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment